Introduction
Stroke is a leading cause of disability and death in China [1] . There is an estimated 33 million people with stroke, many of whom suffer from stroke-related disability [2] . In Korea, the second most common cause of death is stroke, and the treatment and management of stroke incur a large financial burden [3] .
Stroke survivors often suffer from urinary incontinence, dysarthria, limbic paralysis, swallowing deficit, dysphasia, and consciousness disorder [4] . Unfortunately, there are no groundbreaking treatments for these symptoms.. In Korea and China, herbal medicines have been used to treat the diverse symptoms of stroke since ancient times [5] . Herbal medicine treatment is widely known to be effective in the treatment of stroke. [6] .
In past decades, there have been many studies in Korea and China on the effectiveness or efficacy of herbal medicines for stroke in humans. However, recent changes in the health care system indicate that the two countries' use of herbal medicine is different.
In this review, we will investigate characteristics of clinical studies related to the usage of herbal formulas that are widely studied in traditional Korean medicine (TKM) and traditional Chinese Medicine (TCM) for the treatment of stroke symptoms. We will investigate the application of the pattern identification theory, which is used for usage of herbal medicines in the two countries, so that it can be used as the basis for future joint research.
Materials and Methods

Data sources
The following Korean and Chinese databases will be searched from their inception through to August 2017. Study selection will be documented and summarized in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) compliant flow chart (http://www.prismastatement.org).
Search strategy
The search will be conducted in Korean, Chinese, and English using the following terms: stroke OR ischemic stroke OR cerebral infarction OR cerebral hemorrhage OR cerebrovascular accident (CVA) AND herbal medicine OR traditional medicine OR medicinal plant OR Korean medicine OR Chinese medicine.
Eligibility criteria
Population
Patients without limitations on age or sex will be included if they were diagnosed with stroke as confirmed by purely clinical features or by radiological examination (computed tomography, magnetic resonance imaging). Patients with ischemic and hemorrhagic stroke but not subarachnoid hemorrhage or subdural hematoma will be considered for inclusion in the review.
Interventions
Studies reporting any type of herbal medicine treatment; decoction, pill and granules will be included. Herbal medicine treatment could be used alone or combined with routine pharmacotherapy. Studies where the pharmacotherapy administered to the control group is different from the pharmacotherapy administered to the intervention group will be excluded. Trials in which the intervention group includes other TCM therapies in addition to herbal treatment (e.g., acupuncture, moxibustion, massage, tai chi) will be excluded. Also, herbal medicine which were not prescribed by TKM or TCM doctors will be excluded.
Comparators
Comparators will include placebo control, no treatment, routine pharmacotherapy, routine care, and other conventional treatments including western drugs.
Characteristics of included studies 1. Type of herbal formula for stroke 2. Chief complaint of stroke treated by herbal medicine 3. Assessment of the effectiveness of each herbal medicine 4. Pattern type in response based on TKM or TCM theory 5. Range of dosage of herbal formulas 6. Duration of treatment (treatment period calculated according to symptoms) 7. Details of composition of formulas 8. Adverse events
Study design
To prevent the loss of data as far as possible, research methodology will not be restricted when selecting studies for inclusion. Hence, randomized controlled trials (RCTs) nonrandomized controlled clinical trials (CCTs), will be included. All clinical studies will be included if they are studies of herbal medicine therapy, either as sole treatment or as an adjunct to other treatments.
Data extraction
The hard copies of all articles will be obtained and read in full. The selected studies will be classified into RCTs, CCTs, case series, and case reports according to study design. Two authors (YYL and JAL) will perform data extraction using a predefined data. From each study, information about the syndrome for which a prescription was used, the prescription, the prescribed medicine, and its action will be extracted. The data screening and selection process will be performed independently by an author (TYC) who is fluent in Chinese.
Data synthesis
SAS version 9.4 for Windows (SAS Institute Inc., Cary, NC, USA) will be used to analyze the frequencies and patterns of formulas or single herb usage and herbal medicine utilization. Categorical data will be presented as absolute numbers and percentages, and continuous data will be presented as means ± standard deviations.
Discussion
Stroke is the leading cause of death worldwide. Therefore, there is much research on the diagnosis of stroke and its treatment [7] [8] [9] [10] . In the field of traditional medicine, many studies on stroke have been conducted in China, Korea and other East Asian countries [11] [12] [13] , which includes studies on the effectiveness of different types of herbal medicine for stroke [14, 15] . Some herbal medicines appear to be effective for the prevention and treatment of stroke [16, 17] .
Both Korea and China use traditional medicine extensively, but the two countries do not have an up-to-date knowledge on their current state of research nor have they collaborated on research into this area. TCM and TKM have changed a lot in terms of different medical systems and laws. We intend to share basic information on herbal medicine treatment for stroke.. The purpose of this study is to identify the types and effects of TKM and TCM that are widely used in China and Korea, and to apply them to future studies of stroke, particularly in joint clinical research between Korea and China.
Ethics and dissemination
Given that this protocol is for a systematic review, ethics approval is not required. The findings of this review will be disseminated widely through peer-reviewed publications and conference presentations.
